MedTrace Logo

REVerse Intestinal Metaplasia in the Stomach (REVISE)

NCT06590454 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-02-12

No results posted yet for this study

Summary

This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment.

A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.

Conditions

  • Gastric Intestinal Metaplasia
  • Gastric Precancer

Interventions

DRUG

Pyrvinium

Pyrvinium (2 mg/kg) per day for 14 days

DRUG

Placebo

Placebo for 14 days

Sponsors & Collaborators

  • Katherine Garman

    lead OTHER

Principal Investigators

  • Katherine Garman, MD · Duke Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-15
Primary Completion
2026-10-01
Completion
2026-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590454 on ClinicalTrials.gov